| Literature DB >> 25373427 |
Jiae Choi, Ji Hee Jun, Byoung Kab Kang, Kun Hyung Kim, Myeong Soo Lee1.
Abstract
The aim of this study was to assess the endorsement of reporting guidelines in Korean traditional medicine (TM) journals by reviewing their instructions to authors. We examined the instructions to authors in all of the TM journals published in Korea to assess the appropriate use of reporting guidelines for research studies. The randomized controlled trials (RCTs) published after 2010 in journals that endorsed reporting guidelines were obtained. The reporting quality was assessed using the following guidelines: the 38-item Consolidated Standards of Reporting Trials (CONSORT) statement for non-pharmacological trials (NPT); the 17-item Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) statement, instead of the 5-item CONSORT for acupuncture trials; and the 22-item CONSORT extensions for herbal medicine trials. The overall item score was calculated and expressed as a proportion.One journal that endorsed reporting guidelines was identified. Twenty-nine RCTs published in this journal after 2010 met the selection criteria. General editorial policies such as those of the International Committee of Medical Journal Editors (ICMJE) were endorsed by 15 journals. In each of the CONSORT-NPT articles, 21.6 to 56.8% of the items were reported, with an average of 11.3 items (29.7%) being reported. In the 24 RCTs (24/29, 82.8%) appraised using the STRICTA items, an average of 10.6 items (62.5%) were addressed, with a range of 41.2 to 100%. For the herbal intervention reporting, 17 items (77.27%) were reported. In the RCT studies before and after the endorsement of CONSORT and STRICTA guidelines by each journal, all of the STRICTA items had significant improvement, whereas the CONSORT-NPT items improved without statistical significance.The endorsement of reporting guidelines is limited in the TM journals in Korea. Authors should adhere to the reporting guidelines, and editorial departments should refer authors to the various reporting guidelines to improve the quality of their articles.Entities:
Mesh:
Year: 2014 PMID: 25373427 PMCID: PMC4236494 DOI: 10.1186/1745-6215-15-429
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Figure 1Flowchart of journal and articles through the phase screening and eligibility evaluation.
The list of traditional medicine (TM) journals searched in reporting quality review
| Journal title (Abbreviation) | ISSN | Website | Reference to general editorial policies a | Reporting guidelines specific in instructions to authors b |
|---|---|---|---|---|
|
| 1010-0695 |
| ICNJE | nr |
|
| 2287-3368 |
| ICNJE | nr |
|
| 1738-7698 |
| nr | nr |
|
| 1229-1765 |
| ICNJE | nr |
|
| N/A |
| nr | nr |
|
| 1229-2621 |
| ICNJE | nr |
|
| 2093-6966 |
| nr | nr |
|
| 2005-2901 |
| ICNJE | nr |
|
| 1226-7066 |
| ICNJE | nr |
|
| N/A |
| nr | nr |
|
| 1598-1843 |
| nr | nr |
|
| 1229-1137 |
| nr | CONSORT, STARD, STROBE, QUOROM, MOOSE, STRICTA |
|
| 1226-9174 |
| nr | nr |
|
| 1229-4292 |
| nr | nr |
|
| 1226-8038 |
| ICNJE | nr |
|
| 1226-6396 |
| ICNJE | nr |
|
| 1738-6640 |
| ICNJE | nr |
|
| 1598-592X |
| nr | nr |
|
| 1226-5241 |
| ICNJE | |
|
| 1229-1218 |
| nr | nr |
|
| 1229-8328 |
| nr | nr |
|
| 1229-8328 |
| nr | nr |
|
| 1226-4075 |
| nr | nr |
|
| 1975-2407 |
| nr | nr |
|
| 1598-1630 |
| ICNJE | |
|
| 1229-6147 |
| nr | nr |
|
| 1976-9334 |
| ICNJE, Helsinki Declaration, NIH Guide for the Care and Use of Laboratory Animals | |
|
| 1229-1854 |
| ICNJE | nr |
|
| 1598-2386 |
| nr | nr |
|
| 1226-4938 |
| nr | nr |
|
| 2213-4200 |
| ICNJE | |
|
| 1226-8453 |
| ICMJE, COPE, Good Publication Practice for Medical Journals Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication, Helsinki Declaration, AEC | |
|
| 0253-3073 |
| nr | nr |
|
| 0253-3070 |
| nr | nr |
|
| 0252-9777 |
| nr | nr |
|
| 2233-8985 |
| nr | nr |
AEC: Institutional Animal Ethical Committee; COPE: Committee on Publication Ethics; CONSORT: Consolidated Standards of Reporting Trials; ICMJE: International Committee of Medical Journal Editors; MOOSE: Meta-analysis of Observational Studies in Epidemiology; nr: not reported; QUOROM: Quality of Reporting of Meta-analyses; STARD: Standards for Reporting of Diagnostic Accuracy Studies; STROBE: Strengthening the Reporting of Observational Studies in Epidemiology; STRICTA: Standards for Reporting Interventions in Clinical Trials of Acupuncture.
aReference to general editorial policies: whether the journals mentioned to general editorial policies.
bReporting guidance specific in introduction to authors: whether the ‘introduction to authors’ section of a journal provided any reporting guidance.
The reporting number and percentage for each item according to intervention in endorsing journal for reporting guidelines
| CONSORT-NPT | STRICTA (Total number of items = 17) | ||||
|---|---|---|---|---|---|
| Intervention | Author (year) | Nunber of reported items | Percent (%) | Number of reported items | Percent (%) |
| Acupuncture (Total number of items = 37) | Park (2010) [ | 11 | 29.7 | 12 | 70.6 |
| Lee (2010) [ | 11 | 29.7 | 11 | 64.7 | |
| Kim (2010) [ | 9 | 24.3 | 10 | 58.8 | |
| Kwon (2010) [ | 8 | 21.6 | 11 | 64.7 | |
| Joung (2010) [ | 10 | 27.0 | 9 | 52.9 | |
| Yoon (2010) [ | 9 | 24.3 | 14 | 82.4 | |
| Kim (2010) [ | 10 | 27.0 | 17 | 100.0 | |
| Chung (2010) [ | 21 | 56.8 | 9 | 52.9 | |
| Choi (2010) [ | 10 | 27.0 | 10 | 58.8 | |
| Jang (2010) [ | 12 | 32.4 | 9 | 52.9 | |
| Kim (2011) [ | 13 | 35.1 | 9 | 52.9 | |
| Park (2011) [ | 12 | 32.4 | 10 | 58.8 | |
| Park (2011) [ | 11 | 29.7 | 9 | 52.9 | |
| Lee (2011) [ | 9 | 24.3 | 11 | 64.7 | |
| Jeong (2011) [ | 9 | 24.3 | 9 | 52.9 | |
| Shin (2011) [ | 10 | 27.0 | 7 | 41.2 | |
| Lee (2011) [ | 12 | 32.4 | 9 | 52.9 | |
| Im (2011) [ | 10 | 27.0 | 9 | 52.9 | |
| Kim (2011) [ | 10 | 27.0 | 11 | 64.7 | |
| Han (2011) [ | 11 | 29.7 | 13 | 76.5 | |
| Kim (2012) [ | 19 | 51.4 | 10 | 58.5 | |
| Kim (2012) [ | 11 | 29.7 | 9 | 52.9 | |
| Kim (2013) [ | 11 | 29.7 | 10 | 58.8 | |
| Kim (2013) [ | 19 | 51.4 | 17 | 100.0 | |
| Moxibustion (Total number of items = 38) | Cho (2010) [ | 8 | 21.1 | ||
| Lee (2012) [ | 9 | 23.7 | - | - | |
| Kim (2013) [ | 12 | 31.6 | - | - | |
| Cupping (Total number of items = 38) | |||||
| Kim (2013) [ | 9 | 23.7 | - | - | |
| Herbal medicine (Total number of items = 22) | |||||
| Song (2012) [ | 17 | 77.2 | - | - | |
CONSORT-NPT: Consolidated Standards of Reporting Trials with the non-pharmacological trials extension; STRICTA: Standards for Reporting Interventions in Clinical Trials of Acupuncture.
Values are presented as number of reported items divided by the total number of items.
Intervention on CONSORT-NPT included acupuncture, moxibustion and cupping intervention article besides herbal medicine intervention.
aThis article included flow participant diagram.
bThis article included trial registration or protocol information.
The reporting number and percentage for each item of CONSORT 2010 checklist with the non-pharmacological trials extension
| Section/topic | Descriptor summary (Additional items from the non-pharmacological trials extension) | 28 RCTs included in CONSORT endorsing journal | |
|---|---|---|---|
| Number of RCTs | Percent (%) | ||
| Title and abstract | |||
| 1.a) Identification as a randomized trial in the title | 3 | 10.71 | |
| 1.b) Structured summary of trial design, methods, results, and conclusions; for specific guidance (In the abstract, description of the experimental treatment, comparator, care providers, centers and blinding status.) | 2 | 7.14 | |
| Total section (average) | 2.5 | 8.93 | |
| Introduction | |||
| Background and objectives | 2.a) Scientific background and explanation of rationale | 28 | 100 |
| 2.b) Specific objectives or hypotheses | 28 | 100 | |
| Total section (average) | 28 | 100 | |
| Methods | |||
| Trial design | 3.a) Description of trial design (for example, parallel, factorial) including allocation ratio | 4 | 13.79 |
| 3.b) Important changes to methods after trial commencement with reasons | 0 | 0.00 | |
| Participants | 4.a) Eligibility criteria for participants (When applicable, eligibility criteria for centers and those performing the interventions.) | 23 | 79.31 |
| 4.b) Settings and locations where the data were collected | 23 | 79.31 | |
| Interventions | 5) Precise details of both the experimental treatment and comparator | - | - |
| Outcomes | 6.a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed | 17 | 58.62 |
| 6.b) Any changes to trial outcomes after the trial commenced with reasons | 1 | 3.45 | |
| Sample size | 7.a) How sample size was determined (When applicable, details of whether and how the clustering by care providers or centers was addressed.) | 0 | 0.00 |
| 7.b) When applicable, explanation of any interim analyses and stopping guidelines | 0 | 0.00 | |
| Total section (average) | 8.5 | 29.31 | |
| Randomization | |||
| Sequence generation | 8.a) Method used to generate the random allocation sequence (When applicable, how care providers were allocated to each trial group.) | 8 | 28.57 |
| 8.b) Type of randomization; details of any restriction (for example, blocking and block size.) | 3 | 10.71 | |
| Allocation concealment | 9) Mechanism used to implement the random allocation sequence (for example, sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | 1 | 3.57 |
| Implementation | 10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | 5 | 17.86 |
| Blinding | 11.a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how (Whether or not those administering co-interventions were blinded to group assignment. If blinded, method of blinding and description of the similarity of interventions.) | 4 | 14.29 |
| 11.b) If relevant, description of the similarity of interventions | 1 | 3.57 | |
| Statistical methods | 12.a) Statistical methods used to compare groups for primary and secondary outcomes (When applicable, details of whether and how the clustering by care providers or centers was addressed.) | 0 | 0.00 |
| 12.b) Methods for additional analyses, such as subgroup analyses and adjusted analyses | 0 | 0.00 | |
| Total section (average) | 2.75 | 9.82 | |
| Results | |||
| Participant flow (A diagram is strongly recommended) | 13.a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome (The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider or in each center.) | 23 | 82.14 |
| 13.b) For each group, losses and exclusions after randomization, together with reasons | 5 | 17.86 | |
| Implementation of intervention | Details of the experimental treatment and comparator as they were implemented | 25 | 89.29 |
| Recruitment | 14.a) Dates defining the periods of recruitment and follow-up | 22 | 78.57 |
| 14.b) Why the trial ended or was stopped | 1 | 3.57 | |
| Baseline data | 15) A table showing baseline demographic and clinical characteristics for each group (When applicable, descriptions of care providers (case volume, qualification, expertise, and so on) and centers (volume) in each group.) | 10 | 35.71 |
| Numbers analyzed | 16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups | 3 | 10.71 |
| Outcomes and estimation | 17.a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (for example, 95% confidence interval) | 27 | 96.43 |
| 17.b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended | 1 | 3.57 | |
| Ancillary analyses | 18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory | 1 | 3.57 |
| Harms | 19) All important harms or unintended effects in each group; for specific guidance see CONSORT for harms | 6 | 21.43 |
| Total section (average) | 11.3 | 40.26 | |
| Discussion | |||
| Limitations | 20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses | 20 | 71.43 |
| Generalizability | 21) Generalizability (external validity) of the trial findings according to the intervention, comparators, patients and care providers and centers involved in the trial | 2 | 7.14 |
| Interpretation | 22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence (In addition, take into account the choice of the comparator, lack of or partial blinding, unequal expertise of care providers or centers in each group.) | 2 | 7.14 |
| Total section (average) | 8 | 28.57 | |
| Other information | |||
| Registration | 23) Registration number and name of trial registry | 2 | 7.14 |
| Protocol | 24) Where the full trial protocol can be accessed, if available | 2 | 7.14 |
| Funding | 25) Sources of funding and other support (for example, supply of drugs); role of funders | 9 | 32.14 |
| Total section (average) | 4.3 | 15.48 | |
| Total | 11.28 | 29.6 | |
CONSORT-NPT: Consolidated Standards of Reporting Trials with the non-pharmacological trials extension.
Values are presented as number of reported RCTs divided by the total number of eligible RCTs.
Intervention on non-pharmacological trials included moxibustion and cupping intervention article besides acupuncture and herbal medicine intervention.
The reporting number and percentage for each item of STRICTA 2010 checklist of information
| Items | Detail | 24 acupuncture trials | |
|---|---|---|---|
| Number of RCTs | Percent (%) | ||
| 1. Acupuncture rationale | 1a) Style of acupuncture | 23 | 95.8 |
| 1b) Reasoning for treatment provided, based on historical context, literature sources, and/or consensus methods, with references where appropriate | 19 | 79.2 | |
| 1c) Extent to which treatment was varied | 3 | 12.5 | |
| Total section (average) | 15 | 62.5 | |
| 2. Details of needling | 2a) Number of needle insertions per subject per session (mean and range where relevant) | 11 | 45.8 |
| 2b) Names (or location if no standard name) of points used (uni/bilateral) | 23 | 95.8 | |
| 2c) Depth of insertion, based on a specified unit of measurement, or on a particular tissue level | 15 | 62.5 | |
| 2d) Response sought | 4 | 16.7 | |
| 2e) Needle stimulation | 15 | 62.5 | |
| 2f) Needle retention time | 19 | 79.2 | |
| 2g) Needle type | 21 | 87.5 | |
| Total section (average) | 15.4 | 64.3 | |
| 3. Treatment regimen | 3a) Number of treatment sessions | 13 | 54.2 |
| 3b) Frequency and duration of treatment sessions | 19 | 79.2 | |
| Total section (average) | 16 | 66.7 | |
| 4. Other components of treatment | 4a) Details of other interventions administered to the acupuncture group (for example, moxibustion, cupping, herbs, exercises, lifestyle advice) | 17 | 70.8 |
| 4b) Setting and context of treatment, including instructions to practitioners, and information and explanations to patients | 6 | 25.0 | |
| Total section (average) | 11.5 | 47.9 | |
| 5. Practitioner background | 5) Description of participating acupuncturists (qualification or professional affiliation, years in acupuncture practice, other relevant experience) | 14 | 58.3 |
| Total section (average) | 14 | 58.3 | |
| 6. Control or comparator interventions | 6a) Rationale for the control or comparator in the context of the research question, with sources that justify this choice | 10 | 41.7 |
| 6b) Precise description of the control or comparator. If sham acupuncture or any other type of acupuncture-like control is used, provide details as for items 1 to 3 above. | 23 | 95.8 | |
| Total section (average) | 16.5 | 68.8 | |
| Total | 10.6 | 62.5 | |
STRICTA: Standards for Reporting Interventions in Clinical Trials of Acupuncture.
This checklist is designed to replace CONSORT 2010’s item 5 when reporting an acupuncture trial.
Values are presented as number of reported RCTs divided by the total number of eligible RCTs.
Comparison of reported items in journals that did and did not promote adherence to CONSORT and STRICTA statement
| CONSORT-NPT | STRICTA | |||
|---|---|---|---|---|
| Before 2013 | After 2013 | Before 2013 | After 2013 | |
| Number of items reported/total number of items | 282/912 | 51/150 | 228/391 | 27/34 |
| Percent reported items in RCTs (n/N)a | 30.9 | 34.0 | 58.3 | 79.4 |
| Difference in percent between the two groups (CI)b | 3.1 (-5.0 to 11.2) | 21.1 (6.6 to 35.5) | ||
|
| 0.4592 | 0.0042 | ||
CONSORT-NPT: Consolidated Standards of Reporting Trials with the non-pharmacological trials extension; STRICTA: Standards for Reporting Interventions in Clinical Trials of Acupuncture; RCT: randomized controlled trials.
an/N: number of times reported/total number of items evaluated.
b95% confidence intervals (%).
P-value calculated for each of these before after comparisons.